浏览全部资源
扫码关注微信
- Journal Information
- Archive
- Submission
- For Reviewers
- Statement and Policies
Influence of
GLCCI1 gene rs37973 polymorphism on the efficacy of ICSs in the treatment of asthma-chronic obstructive pulmonary disease overlap- ZHONGGUO YAOFANG Vol. 34, Issue 20, Pages: 2535-2539(2023)
- 作者机构：
1.上海市浦东新区人民医院药剂科，上海 201200
2.上海交通大学医学院附属瑞金医院药剂科，上海 200025
- 作者简介：
- 基金信息：
DOI：10.6039/j.issn.1001-0408.2023.20.16
CLC： R977.1;R563Published：30 October 2023，
Received：10 July 2023，
Revised：22 September 2023，
扫 描 看 全 文
邱彦,董雅芬,于平等.GLCCI1基因rs37973位点多态性对ICSs治疗哮喘-慢性阻塞性肺疾病重叠效果的影响 Δ[J].中国药房,2023,34(20):2535-2539.
QIU Yan,DONG Yafen,YU Ping,et al.Influence of GLCCI1 gene rs37973 polymorphism on the efficacy of ICSs in the treatment of asthma-chronic obstructive pulmonary disease overlap[J].ZHONGGUO YAOFANG,2023,34(20):2535-2539.
邱彦,董雅芬,于平等.GLCCI1基因rs37973位点多态性对ICSs治疗哮喘-慢性阻塞性肺疾病重叠效果的影响 Δ[J].中国药房,2023,34(20):2535-2539. DOI： 10.6039/j.issn.1001-0408.2023.20.16.
QIU Yan,DONG Yafen,YU Ping,et al.Influence of GLCCI1 gene rs37973 polymorphism on the efficacy of ICSs in the treatment of asthma-chronic obstructive pulmonary disease overlap[J].ZHONGGUO YAOFANG,2023,34(20):2535-2539. DOI： 10.6039/j.issn.1001-0408.2023.20.16.
摘要
目的
2
探讨
GLCCI1
基因rs37973位点多态性与哮喘-慢性阻塞性肺疾病重叠（ACO）患者使用吸入性糖皮质激素（ICSs）后应答反应的相关性。
方法
2
纳入2019年4月1日至2020年12月31日就诊于上海市浦东新区人民医院并首次诊断为ACO的患者173例。所有患者均使用沙美特罗替卡松吸入粉雾剂，每天2次，持续24周。测定患者的rs37973位点基因型和肺功能指标[第1秒用力呼气容积（FEV
1
）、FEV
1
/用力肺活量（FVC）、FEV
1
占预计值百分比（FEV
1
%pred）]及肺功能改善情况（ΔFEV
1
和ΔFEV
1
%pre）。
结果
2
共有111例患者完成了24周随访及肺功能检测，其中，
GLCCI1
基因rs37973位点AA型42例、AG型52例、GG型17例。治疗12、24周后，患者的肺功能指标总体情况均显著优于治疗前患者的基线肺功能指标（
P
＜0.05）。治疗24周后，AA型、AG型患者的肺功能改善情况均显著优于GG型，且AA型患者的ΔFEV
1
%pred显著优于AG型（
P
＜0.05）。治疗12、24周后，吸烟史≤20包年患者的肺功能改善情况均显著优于吸烟史＞20包年患者，且吸烟史≤20包年患者中仅AA型患者的ΔFEV
1
%pred显著优于AG型（
P
＜0.05）。治疗12周后，吸烟史＞20包年患者中，AA型和AG型患者肺功能改善情况均显著优于GG型，且AA型患者的ΔFEV
1
%pred显著优于AG型（
P
＜0.05）；治疗24周后，AA型和AG型患者的肺功能改善情况均显著优于GG型（
P
＜0.05）。
结论
2
GLCCI1
基因rs37973位点GG型ACO患者对ICSs的治疗反应较其他基因型差，其中吸烟史＞20包年的患者反应更差。
Abstract
OBJECTIVE
2
To investigate the association between the functional
GLCCI1
gene rs37973 polymorphism and inhaled corticosteroids （ICSs） response in patients with asthma-chronic obstructive pulmonary disease overlap （ACO）.
METHODS
2
Totally 173 newly diagnosed ACO patients were recruited from Shanghai Pudong New Area People’s Hospital during April 1st， 2019 to December 31st， 2020. All patients were treated with Salmeterol fluticasone inhalation powder， twice a day， for 24 weeks. The genotype of rs37973 locus was determined， and lung function indicators [forced expiratory volume in one second （FEV
1
）， FEV
1
/forced vital capacity （FVC）， the percentage of FEV
1
to expected value （FEV
1
%pred）]， and lung function improvement （ΔFEV
1
and ΔFEV
1
%pred） were all detected.
RESULTS
2
Totally 111 patients completed the whole 24-week follow-up and lung function detection. Among them， there were 42 cases of AA genotype， 52 cases of AG genotype， and 17 cases of GG genotype. After 12， 24 weeks of treatment， lung function indexes of patients were significantly better than baseline lung function indexes before treatment （
P
＜0.05）. After 24 weeks of treatment， ACO patients with AA and AG genotypes showed significantly better lung function improvement than GG genotype， and ΔFEV
1
%pred of AA genotype was significantly better than AG genotype （
P
＜0.05）. After 12， 24 weeks of treatment， the improvement of lung function in patients with a smoking history ≤20 pack year was significantly better than those with a smoking history ＞20 pack year， and among patients with a smoking history ≤20 pack year， only AA genotype had significantly better FEV
1
%pred than AG genotype （
P
＜0.05）. After 12 weeks of treatment， among patients with a smoking history ＞20 pack year， the improvement of lung function in AA genotype and AG genotype was significantly better than GG genotype， and the FEV
1
%pred in AA genotype was significantly better than AG genotype （
P
＜0.05）. After 24 weeks of treatment， the improvement of lung function of AA genotype and AG genotype was significantly better than GG genotype （
P
＜0.05）.
CONCLUSIONS
2
GG genotype of
GLCCI1
gene rs37973 locus is associated with the poor treatment response to ICSs in patients with ACO， especially in patients with smoking history ＞20 pack year.
关键词
哮喘-慢性阻塞性肺疾病重叠糖皮质激素诱导转录蛋白1抗体单核苷酸多态性吸入性糖皮质激素
Keywords
glucocorticoid-induced transcript 1single nucleotide polymorphismsinhaled corticosteroids
references
GBD Chronic Respiratory Diseases Collaborators. Global burden of chronic respiratory diseases and risk factors，1990-2019：an update from the Global Burden of Disease Study 2019[J]. EClinicalMedicine，2023，59：101936.
Global Initiative for Asthma，Global Initiative for Chronic Obstructive Lung Disease. Diagnosis of diseases of chronic airflow limitation：asthma COPD and asthma-COPD overlap syndrome（ACOS）[EB/OL].[2022-12-23]. https：//goldcopd.org/wp-content/uploads/2016/04/GOLD_ACOS_2015.pdfhttps://goldcopd.org/wp-content/uploads/2016/04/GOLD_ACOS_2015.pdf.
WOODRUFF P G，VAN DEN BERGE M，BOUCHER R C，et al. American Thoracic Society/national heart，lung，and blood institute asthma-chronic obstructive pulmonary disease overlap workshop report[J]. Am J Respir Crit Care Med，2017，196（3）：375-381.
VAZ FRAGOSO C A，MURPHY T E，AGOGO G O，et al. Asthma-COPD overlap syndrome in the US：a prospective population-based analysis of patient-reported outcomes and health care utilization[J]. Int J Chron Obstruct Pulmon Dis，2017，12：517-527.
HIKICHI M，HASHIMOTO S，GON Y. Asthma and COPD overlap pathophysiology of ACO[J]. Allergol Int，2018，67（2）：179-186.
SIN D D，MIRAVITLLES M，MANNINO D M，et al. What is asthma-COPD overlap syndrome? Towards a consensus definition from a round table discussion[J]. Eur Respir J，2016，48（3）：664-673.
JANG A S，LEE J H，PARK S W，et al. Factors influen-cing the responsiveness to inhaled glucocorticoids of patients with moderate-to-severe asthma[J]. Chest，2005，128（3）：1140-1145.
TANTISIRA K G，LASKY-SU J，HARADA M，et al. Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma[J]. N Engl J Med，2011，365（13）：1173-1183.
RIJAVEC M，ŽAVBI M，LOPERT A，et al. GLCCI1 polymorphism rs37973 and response to treatment of asthma with inhaled corticosteroids[J]. J Investig Allergol Clin Immunol，2018，28（3）：165-171.
LEI Y，GAO Y P，CHEN J K，et al. GLCCI1 rs37973：a potential genetic predictor of therapeutic response to inhaled corticosteroids in Chinese chronic obstructive pulmonary disease patients[J]. Sci Rep，2017，7：42552.
HARDIN M，CHO M，MCDONALD M L，et al. The clinical and genetic features of COPD-asthma overlap syndrome[J]. Eur Respir J，2014，44（2）：341-350.
MILLER M R，HANKINSON J，BRUSASCO V，et al. Standardisation of spirometry[J]. Eur Respir J，2005，26（2）：319-338.
CGS Report. Terminology，definitions，and classification of chronic pulmonary emphysema and related conditions[J]. Thorax，1959，14（4）：286-299．
POSTMA D S，WEISS S T，VAN DEN BERGE M，et al. Revisiting the Dutch hypothesis[J]. J Allergy Clin Immunol，2015，136（3）：521-529.
MIRAVITLLES M. Asthma-COPD overlap（ACO）PRO-CON debate. ACO：call me by my name[J]. COPD，2020，17（5）：471-473.
CHAPMAN M S，QU N，PASCOE S，et al. Isolation of differentially expressed sequence tags from steroid-responsive cells using mRNA differential display[J]. Mol Cell Endocrinol，1995，108（1/2）：R1-R7.
IZUHARA Y，MATSUMOTO H，KANEMITSU Y，et al. GLCCI1 variant accelerates pulmonary function decline in patients with asthma receiving inhaled corticosteroids[J]. Allergy，2014，69（5）：668-673.
POSTMA D S，KERKHOF M，BOEZEN H M，et al. Asthma and chronic obstructive pulmonary disease：common genes，common environments?[J]. Am J Respir Crit Care Med，2011，183（12）：1588-1594.
ANTHONISEN N R，CONNETT J E，MURRAY R P. Smoking and lung function of lung health study participants after 11 years[J]. Am J Respir Crit Care Med，2002，166（5）：675-679.
MIRAVITLLES M. Diagnosis of asthma-COPD overlap：the five commandments[J]. Eur Respir J，2017，49（5）：1700506.
0
Views
0
下载量
0
CSCD
- L-PDFDownload
- WORDDownload
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
- Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号
公网安备50010302001817 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.